S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Laser breakthrough could send stock soaring 2,467% (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Laser breakthrough could send stock soaring 2,467% (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Laser breakthrough could send stock soaring 2,467% (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Laser breakthrough could send stock soaring 2,467% (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

NKGen Biotech (NKGN) Competitors

$1.00
+0.05 (+5.26%)
(As of 02/22/2024 ET)

NKGN vs. SABS, FRLN, SRZN, APTO, ENTX, PLUR, INKT, ZIVO, INAB, and AIM

Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include SAB Biotherapeutics (SABS), Freeline Therapeutics (FRLN), Surrozen (SRZN), Aptose Biosciences (APTO), Entera Bio (ENTX), Pluri (PLUR), MiNK Therapeutics (INKT), ZIVO Bioscience (ZIVO), IN8bio (INAB), and AIM ImmunoTech (AIM). These companies are all part of the "medical" sector.

NKGen Biotech vs.

NKGen Biotech (NYSE:NKGN) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.

NKGen Biotech has higher earnings, but lower revenue than SAB Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A$4.55MN/AN/A
SAB Biotherapeutics$23.90M1.09-$18.74MN/AN/A

SAB Biotherapeutics has a consensus price target of $10.00, indicating a potential upside of 100.80%. Given SAB Biotherapeutics' higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
SAB Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

28.5% of NKGen Biotech shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by insiders. Comparatively, 26.0% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NKGen Biotech has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

SAB Biotherapeutics received 13 more outperform votes than NKGen Biotech when rated by MarketBeat users.

CompanyUnderperformOutperform
NKGen BiotechN/AN/A
SAB BiotherapeuticsOutperform Votes
13
68.42%
Underperform Votes
6
31.58%

NKGen Biotech has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -664.68%. NKGen Biotech's return on equity of -2.50% beat SAB Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A -2.50% -24.01%
SAB Biotherapeutics -664.68%-120.36%-69.17%

In the previous week, NKGen Biotech had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for NKGen Biotech and 0 mentions for SAB Biotherapeutics. NKGen Biotech's average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
SAB Biotherapeutics Neutral

Summary

NKGen Biotech and SAB Biotherapeutics tied by winning 6 of the 12 factors compared between the two stocks.


Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGN vs. The Competition

MetricNKGen BiotechBiotechnology IndustryMedical SectorNYSE Exchange
Market Cap$21.89M$555.24M$5.14B$17.38B
Dividend YieldN/A3.47%2.90%3.57%
P/E RatioN/A246.42133.6424.83
Price / SalesN/A18,583.633,084.735.69
Price / Cash5.9411.2989.2617.89
Price / Book-5.265.204.306.35
Net Income$4.55M-$34.35M$112.74M$869.26M
7 Day Performance-33.33%0.09%0.43%-0.59%
1 Month Performance-61.83%3.74%6.41%1.86%
1 Year PerformanceN/A64.05%8.13%87.64%

NKGen Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SABS
SAB Biotherapeutics
2.3404 of 5 stars
$5.24
-4.6%
$10.00
+90.8%
+643.3%$27.42M$23.90M0.0056Gap Up
FRLN
Freeline Therapeutics
2.091 of 5 stars
$6.48
flat
$11.13
+71.7%
N/A$28.12MN/A-1.16152
SRZN
Surrozen
0 of 5 stars
$13.99
+17.9%
N/A-4.3%$28.54M$12.50M-0.8074Gap Down
APTO
Aptose Biosciences
1.4656 of 5 stars
$1.95
flat
$36.50
+1,771.8%
-81.3%$29.19MN/A-0.2531Gap Up
ENTX
Entera Bio
1.8307 of 5 stars
$1.07
+1.9%
$10.00
+834.6%
+15.4%$30.82M$130,000.00-3.1519
PLUR
Pluri
0 of 5 stars
$0.78
-6.0%
N/A-26.0%$32.35M$357,000.00-1.34123News Coverage
Gap Down
INKT
MiNK Therapeutics
1.415 of 5 stars
$0.94
+2.2%
$6.50
+592.3%
-53.6%$32.41MN/A-1.2937Negative News
Gap Up
ZIVO
ZIVO Bioscience
0 of 5 stars
$8.20
+2.5%
N/A-57.4%$22.63MN/A0.008News Coverage
Gap Up
INAB
IN8bio
2.6034 of 5 stars
$1.05
-6.3%
$11.00
+952.6%
-43.9%$33.43MN/A-0.9331
AIM
AIM ImmunoTech
0 of 5 stars
$0.42
+10.5%
N/A-19.6%$20.51M$140,000.00-0.9822Gap Up

Related Companies and Tools

This page (NYSE:NKGN) was last updated on 2/23/2024 by MarketBeat.com Staff